Home » UCB SUBMITS NDA FOR RHINITIS TREATMENT
UCB SUBMITS NDA FOR RHINITIS TREATMENT
UCB has submitted a new drug application (NDA) to the FDA for Xyzal (levocetirizine dihydrochloride), a new prescription antihistamine for treatment of allergy symptoms.
UCB requested as part of the FDA application the following indications: seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria in adults and children 6 and older.
The drug was first launched in Europe in 2001 and is currently marketed in 49 countries.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May